|
|
Article: Bicalutamide: Fulminant hepatotoxicity: case report
- Article from:
- Reactions Weekly
- Article date:
- August 9, 2008
- Author:
CopyrightCopyright Wolters Kluwer Health Adis International Aug 9, 2008. Provided by ProQuest LLC. (Hide copyright information)
|
A 59-year-old man developed fulminant hepatotoxicity during treatment with bicalutamide for metastatic prostate cancer: he subsequently died of multiple organ failure.
Upon diagnosis of stage IV prostate cancer with limited metastases, the man began treatment with leuprorelin, bicalutamide [dosage not stated] for 1 month, and chemotherapy with cisplatin and etoposide. After four 21-day cycles of chemotherapy he received radiotherapy, and 3 months after completion, leuprorelin was withheld. New metastases were discovered two months later and bicalutamide [dosage not stated] was restarted. Four days later, after receiving four doses of bicalutamide, he was admitted with abdominal pain, ...